Cibinqo
(Abrocitinib)ApprovedSmall molecule
PfizerAbrocitinib is used to treat moderate to severe atopic dermatitis (eczema), a skin condition that causes itching, inflammation, and irritation. It helps reduce these symptoms by calming down the immune system's overactive response in the skin.[2] Cibinqo is currently approved and in use across 13 indications[4].[1]
Cibinqo is one of 318 small molecule programs targeting Atopic Dermatitis. It is currently in Approved.
13
Indications
28
Total Trials
16
Active Trials
317
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
3
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 12 indications
Competition
Competitive Landscape
134 competitors in Systemic Lupus Erythematosus
#DrugCompanyPhaseTrials
1Cibinqo
PfizerApproved
Rituxan
RochePhase 3
Medrol
PfizerPhase 3
Rinvoq
AbbViePhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Gazyva
RochePhase 3
Sotyktu
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Rapamune
PPrism Pharmaceuticals
Phase 3
Ianalumab
NovartisPhase 3
Fludara
SanofiPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Atopic Dermatitis13 trials
Show 10 more trials
Fatigue1 trial
Study to Investigate the Efficacy of Abrocitinib in Adult Participants With Severe Fatigue From Post COVID Condition/Long COVID
Active, not recruiting·—·Phase 2·NCT06597396·46 enrolled
11 more indications
Oral1 trial
Chronic Hand Eczema1 trial
Prurigo Nodularis1 trial
Pregnant Women and Their Offspring1 trial
Efficacy and Safety1 trial
Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University··NCT06573593·150 enrolled
Toxic Epidermal Necrolysis1 trial
Caffeine1 trial
Eczema1 trial
Diabetes Mellitus, Type 11 trial
A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Subtype-Selective JAK Inhibitors for Preservation of Pancreatic β Cell Function in Newly Diagnosed Type 1 Diabetes Mellitus
Active, not recruiting·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT05743244·78 enrolled
Regulatory
FDA Approval Timeline[5]
Jan 14, 2022
CIBINQO
NDA NDA213871
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Cibinqo drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Abrocitinib. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]